Efgartigimod for IVIG-dependent myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have a positive antibody test for myasthenia gravis (AChR antibodies).
- You have been on regular IVIG treatments for at least one year with a stable dose and no major changes in your condition for the past 4 months.
- You haven't changed or added certain medications (called NSISTs) in the last 6 months or steroids in the last 3 months.
- You cannot have had rituximab, eculizumab, or plasma exchange in the last 6 months, or a thymectomy in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are experiencing a sudden, severe worsening of symptoms (crisis). The drug may help reduce the need for a breathing tube or speed up recovery.
Hear when a new Myasthaenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.